Pancreatic cancer can be cured mainly when surgery removes it all, and only about 1 in 5 people can have that surgery when they are diagnosed. About 14% of people are alive five years after diagnosis, and about 3% once it has spread. There is still no cure for cancer that has spread. Our view: drugs that switch off RAS, the gene that drives about 9 in 10 cases, are the biggest change in decades. Whether they can raise the cure rate depends on trials now testing them earlier, right after diagnosis and after surgery.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with an oncologist, ideally at a center that treats many pancreatic cancers. Ask about tumor and genetic testing, which can open up treatment options.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your oncologist.
After surgery, leftover cancer is tiny and, by our inference, may not yet resist RAS drugs. Could people whose blood still shows tumor DNA be treated with a RAS drug plus an immune treatment that helps T cells finish the job, and stay free of cancer longer than with a RAS drug alone? The immune partner may be a drug that does not yet exist.
What would prove it wrong: if adding immune help to a RAS drug does not clear blood tumor DNA or delay relapse more than the RAS drug alone in people with leftover disease.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Researchers report that cancer-associated fibroblasts (support cells around the tumor) pass fats, including cholesterol, to pancreatic cancer cells by a process called trogocytosis, which needs a protein called ANO6. The same process helped these cells suppress immune T cells. Blocking ANO6 slowed tumor growth in lab and animal models. Some authors hold a patent on ANO6 inhibitors. This is early lab research and has not been tested in patients.
Using 242 tumor organoids grown from patients, researchers found a subset of KRAS G12D tumors that resist KRAS-blocking drugs and have weak interferon (immune) signaling. In lab models, adding interferon beta made resistant tumors more sensitive to KRAS inhibitors, including RMC-6236 (daraxonrasib). A lab study only; it has not been tested in patients.
In 74 people with high-risk pancreatic cancer that had not spread, adding stereotactic body radiotherapy (SBRT, precise high-dose radiation) to chemo cut the chance the cancer returned near the pancreas within 12 months to 20.2% vs 52.0% with chemo alone. Serious side effects were similar (70% vs 64%). The trial closed early because few people joined, so it was smaller than planned and needs larger studies. Survival results were not reported in the abstract.
In AMPLIFY-7P, 144 people with KRAS-mutated pancreatic cancer who had no relapse after standard treatment were assigned 2:1 to the vaccine (96) or observation (48). Time without relapse was 23.8 vs 21.2 months, not a significant difference (the main goal was not met). Later analyses hinted at benefit in some groups, such as people whose tumor DNA was not detectable in blood, but these are exploratory. Side effects were similar to observation. The authors plan a refined Phase 3 trial. Not an approved treatment.
In a Japanese single-arm study of 25 people with locally advanced pancreatic cancer, chemotherapy (gemcitabine plus nab-paclitaxel) with radiation led to a 2-year survival rate of 36.0%, above the 15% threshold the study set. Eight people (32.0%) went on to surgery. Median survival was 20.8 months. Severe (grade 3 or higher) side effects affected 92.0% of patients, and 37.5% of those operated on had major complications. Small, no comparison group; not a standard treatment.
The EMA committee (CHMP) gave a positive opinion for adults with spread pancreatic cancer who had at least one earlier treatment, based on the RASolute 302 trial (median survival 13.2 vs 6.7 months). The European Commission still has to make the final decision. Not yet approved in the EU.
In 28 people with pancreatic cancer that could be removed, two months of gemcitabine plus nab-paclitaxel before surgery allowed surgery in about 86%. Median time without relapse was 15.7 months and median survival 32.9 months, similar to matched patients who had surgery first. Those who finished four cycles trended toward longer survival. Single-arm and small, so it cannot show which approach is better.
Revolution Medicines said it has begun treating patients in its global, randomized, open-label trial of daraxonrasib plus zoldonrasib vs gemcitabine + nab-paclitaxel as first treatment for spread cancer with the KRAS G12D change. Main goals are time without growth and overall survival. Not yet an approved use (company release).
In 112 people with newly diagnosed metastatic pancreatic cancer at 14 sites in the U.S. and Spain, adding VCN-01 (a virus that attacks tumor cells) to gemcitabine and nab-paclitaxel was reported by the company to improve survival, time without progression and response length vs chemo alone, most in the group given two doses. Open-label, mid-stage; it is not an approved treatment.
Resistance takes different routes in KRAS G12D and G12R tumors. In one G12R patient, a trametinib-based combination chosen from lab-grown tumor tests controlled the cancer for about 5 months.
An IL-21 mimic, working through CD4 T cells, turned short responses to KRAS inhibitors into lasting remissions in mice. Human testing has not started.
Researchers pooled nine studies (2,733 people) of first-line chemotherapy for spread pancreatic cancer. They found no statistically significant difference in survival between NALIRIFOX and FOLFIRINOX regimens (HR 1.13, 95% CI 0.71–1.81), but different side effects: more low blood counts with FOLFIRINOX, more diarrhea and low potassium with NALIRIFOX. It compares published trials indirectly, not head to head.
A two-RAS-drug, chemo-free combination for spread cancer with the KRAS G12D change. About 400 patients planned.
BioNTech stopped its colorectal cancer vaccine trial but said the pancreatic trial of autogene cevumeran with atezolizumab and mFOLFIRINOX continues as planned.
For adults with metastatic pancreatic adenocarcinoma after at least one prior treatment, or who can't have multi-drug chemo. Approved 6.5 months ahead of the review deadline.
In 81 patients with KRAS G12D tumors, tumors shrank in 82% with mFOLFIRINOX and 61% with gemcitabine + nab-paclitaxel. Early, small and not yet peer-reviewed.
Europe's regulator is assessing data in stages to speed a decision. No approval date yet.
Did not meet its main goal of longer relapse-free survival in 144 patients. Subgroup signals were found after the fact (company release).
500 patients: median survival 13.2 vs 6.7 months (hazard ratio 0.40), time before growth 7.2 vs 3.6 months. Grade 3 or worse side effects 61.8% vs 69.6%.
Safe to add to gemcitabine + nab-paclitaxel in 36 patients and changed the tumor's surroundings. Oral dosing caused high calcium in 42%. Not a test of survival.
Swapping in S-1 did not help in second-line treatment: median survival 6.0 vs 9.1 months in 120 patients.
In locally advanced cancer, adding SBRT radiation didn't improve survival (28.9 vs 28.1 months). Closed early with only 37 patients.
FDA signed a "safe to proceed" letter on April 30, two days after the request, so patients could get the drug before approval.
In 290 patients, mistletoe injections did not improve quality of life or weight. The authors see no reason to recommend it.
Tests daraxonrasib alone or with gemcitabine + nab-paclitaxel against chemo alone in newly diagnosed spread cancer. About 900 patients planned.
Burning the tumor with RFA did not extend survival (12.1 vs 11.6 months) in 188 patients and lowered quality of life.
The FDA approved Novocure's wearable device, which sends mild electric fields through the body to slow tumor cell division, for adults whose pancreatic cancer has not spread but cannot be removed. It is used with gemcitabine and nab-paclitaxel. In 571 people, median survival was 16.2 months vs 14.2 months with chemo alone, and median time to worse pain was 15.2 vs 9.1 months (company-reported; open-label trial).
Tests whether daraxonrasib after surgery and chemo keeps the cancer away longer than watching. About 500 patients planned.
For decades, progress in pancreatic cancer came in small steps from stronger chemo combinations. In 2026, a targeted pill aimed at RAS nearly doubled survival in spread cancer that had already been treated.
In RASolute 302 (500 patients), median survival was 13.2 months versus 6.7 months on chemo, and tumors shrank in 30% versus 11%. Only 1.2% stopped it because of side effects, versus 11.2% on chemo. Rash and mouth sores are common. It's taken once a day.
Liposomal irinotecan with oxaliplatin, 5-FU and leucovorin. In NAPOLI 3 (770 patients), median survival was 11.1 months versus 9.2 months with gemcitabine plus nab-paclitaxel.
Given after platinum chemo has kept spread cancer in check. In POLO, it doubled the time before the cancer grew (7.4 vs 3.8 months), but overall survival was about the same (18.9 vs 18.1 months). About 5–7% of people with spread disease carry an inherited BRCA change.
Four-drug chemo after surgery. Median survival was 53.5 months versus 35.5 with gemcitabine, and 43.2% versus 31.4% were alive at five years. It's harder to tolerate, so it's for people who are fit enough.
A vaccine made for each patient's tumor. In a Phase 1 study, the 8 patients whose immune systems responded had not reached a median time to relapse after about 3 years, versus 13.4 months in non-responders. The 260-patient IMcode003 trial is testing it with chemo.
In the 144-patient AMPLIFY-7P trial, it did not significantly extend the time without relapse compared with watching. The company points to benefit in some subgroups, but those were looked at after the fact. A useful negative result.
| Treatment | For | What it does |
|---|---|---|
| Surgery (Whipple or distal pancreatectomy) | Cancer that can be fully removed (about 20%) | Removes the tumor. The best chance of long-term survival. |
| mFOLFIRINOX or gemcitabine + capecitabine | After surgery | Chemo to lower the chance of relapse. S-1 is an option in Asia. |
| FOLFIRINOX, NALIRIFOX (2024), gemcitabine + nab-paclitaxel (2013) | First treatment for advanced cancer | Combination chemo that slows the cancer and extends life by months. |
| Daraxonrasib (2026) | Spread cancer after earlier treatment | Daily pill that blocks RAS. Nearly doubled median survival versus chemo. |
| Liposomal irinotecan + 5-FU (2015) | After gemcitabine | Second-line chemo. Median survival 6.1 vs 4.2 months in NAPOLI-1. |
| Olaparib (2019) | Inherited BRCA changes | Maintenance pill after platinum chemo. Delays growth. |
No supplement prevents or cures pancreatic cancer. The best-studied "natural" product, mistletoe, failed in a large trial. What does help is treating the digestion and weight-loss problems this cancer causes. We rate each by the strength of human evidence.
Tested properly in 290 patients against placebo (MISTRAL). It did not extend survival or improve quality of life, and caused skin reactions at the injection site in 66%.
In a 25-patient trial of 8 g a day, 2 people showed some activity. Very little reached the blood. No controlled trial shows it helps.
Many chemo drugs work partly through oxidative damage. In a large breast-cancer study (SWOG S0221), antioxidants during chemo were linked to more relapses. No such study exists for pancreatic cancer, so ask your oncologist first.
A 32-patient trial of a medically supervised keto diet with chemo showed trends toward longer survival (13.7 vs 10.2 months), but it was too small to prove anything. Only try it with a medical team.
About 72% of people with advanced pancreatic cancer can't digest food well. Prescription enzymes with meals were linked to about 3.8 months longer survival in a review of mostly observational studies.
In a 60-patient Japanese trial, an easy-to-digest "elemental" drink during chemo helped keep weight and strength, and survival was longer (21.4 vs 12.8 months). One small trial, so it needs confirming. Work with a dietitian.
In an 80-patient trial in Taiwan, 4 weeks of ear acupressure improved sleep and insomnia during chemo. It doesn't treat the cancer.
A prescription vitamin D-like drug (paricalcitol) is being studied with chemo, but it raised calcium in some patients. Store-bought vitamin D is not a treatment.
Be careful: herbal products and high-dose antioxidants can interfere with chemo, and daraxonrasib already causes rash and mouth sores, so check before adding creams or supplements. Clinics selling "natural" or "immune" cancer cures can delay treatment that works. Tell the oncology team about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
An NCI-designated Comprehensive Cancer Center and, by its own statement, a National Pancreas Foundation Center of Excellence. Its Dr. Eileen O'Reilly was lead author of the RASolute 302 trial report.
Part of the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center. Dr. Brian Wolpin, who directs its Hale Family Center for Pancreatic Cancer Research, led the RASolute 302 trial.
A National Pancreas Foundation Center of Excellence for pancreatic cancer. Columbia's Herbert Irving Comprehensive Cancer Center is NCI-designated, and one of its doctors co-authored the RASolute 302 report.
Recognized in December 2025 as a National Pancreas Foundation Pancreatic Cancer Clinical Center and Academic Center of Excellence. NCI-designated Comprehensive Cancer Center.
Named a National Pancreas Foundation Center of Excellence for pancreatic cancer in October 2025, the only one in South Carolina. NCI-designated Clinical Cancer Center.
Says it treats over 2,000 patients a year, with more than 700 having pancreas surgery (the center's own figures). A Heidelberg University Hospital doctor co-authored the RASolute 302 report.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face pancreatic cancer alone. These groups connect patients, families and caregivers with people who understand. Most are free.
Free one-to-one help from case managers, including finding specialists and clinical trials, plus a Survivor & Caregiver Network for peer support.
Get support ↗A specialist nurse support line by phone, email or WhatsApp, plus "Circles," online peer groups on WhatsApp and Facebook.
Get support ↗A nurse and counsellor helpline and PanSupport groups for people living with pancreatic and other upper GI cancers.
Get support ↗A list of virtual and in-person groups for pancreatic cancer, including weekly peer Zoom calls and caregiver groups.
Find a group ↗A nonprofit online community sharing science-based treatment news, survivor stories, and a clinical trial finder.
Learn more ↗An online community where patients and caregivers learn from each other, with a group for pancreatic cancer.
Join ↗Many private pancreatic cancer and Whipple-surgery groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Pancreatic cancer often moves quickly, and caregivers carry a lot. Most of these groups welcome family members, and PanCAN's case managers can help with trial searches and genetic test results.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Chemo and surgery are similar in most countries. The differences: the new RAS pill is approved only in the U.S. so far, Japan uses the S-1 pill after surgery, and BRCA and liposomal-irinotecan treatments reached Europe a few years after the U.S.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Daraxonrasib (Rasonque)Spread cancer, after earlier treatment | 2026 | Panel backs | — | — | — | — | — | — | — |
| NALIRIFOXFirst treatment, spread cancer | 2024 | 2024 | — | — | — | — | — | — | — |
| Liposomal irinotecan + 5-FUAfter gemcitabine | 2015 | 2016 | — | — | — | — | — | — | — |
| Olaparib (Lynparza)Inherited BRCA, maintenance | 2019 | 2020 | — | — | 2020 | — | — | — | — |
| S-1After surgery | — | — | — | — | Standard care | — | — | — | — |
In 385 Japanese patients, 5-year survival was 44.1% with S-1 versus 24.4% with gemcitabine. It became standard after surgery in Japan, and NCI calls it an option in Asia. S-1 has no record in Drugs@FDA.
A widespread complementary therapy. In a 290-patient placebo-controlled trial, it did not extend survival (7.8 vs 8.3 months) or improve quality of life. Not worth traveling for.
Approved only in the U.S. so far. Europe's drug committee recommended approval on October 15, 2026 after a staged review; the European Commission makes the final decision. Health Canada worked with the FDA on its review, and Japan's regulator observed. Neither has approved it yet as far as we could find.
Most pancreatic cancers start in the cells lining the ducts that carry digestive juices. The first step is almost always a broken RAS gene, usually KRAS, which gets stuck in the "on" position and tells cells to keep growing. Over years, more genes break, and the cancer often spreads before it causes symptoms.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations exist to help people with pancreatic cancer and their families pay for care and costs. Funds are limited and rules vary, so contact each one directly.
A one-time grant, paid straight to the lender, toward rent or mortgage, utilities or medical bills in the patient's name. Its guide gives a maximum of $2,000, not guaranteed. Patients may re-apply after 12 months.
See the program ↗Short-term financial help with essential needs that would otherwise go unmet. There's no online form: contact the foundation and talk with your doctor, nurse navigator or social worker.
See the fund ↗A one-time grant toward costs such as transportation, treatment, home care, pain medicine and childcare. Call CancerCare at (800) 813-4673 and ask for the Hirshberg Pancreatic Program. Hirshberg said in April 2026 that funding was renewed for the first half of 2026.
See the program ↗Helps pay treatment copays from a pancreatic cancer fund. The fund was listed as closed on October 6, 2026; it opens and closes during the year.
Check fund status ↗A pancreatic cancer fund that helps with copays, coinsurance, deductibles and premiums. The fund was listed as closed on October 6, 2026; you can sign up to hear when it reopens.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually sourced: the "ask about tumor and genetic testing" advice and dietitian suggestions reflect standard supportive-care practice rather than a single study. S-1's U.S. status is based on finding no S-1 record in Drugs@FDA. Zoldonrasib results are early congress data, and ELI-002 7P results come from a company release; neither is peer-reviewed yet. Expert care centers: MSK's National Pancreas Foundation status is from MSK's own page, and Heidelberg's patient numbers are the center's own figures; the National Pancreas Foundation's directory blocks automated checks, so it could not be confirmed there. Approvals outside the U.S., EU and Japan (UK, Canada, South Korea, China, Australia, Switzerland) could not be verified from a regulator and are marked "—". No pancreatic-cancer-specific Reddit community could be verified (Reddit blocks automated checks), so none is listed. Financial help: checked October 6, 2026. The Hirshberg program is described only on Hirshberg's pages, not CancerCare's, and no funding after mid-2026 was confirmed. The CancerCare and TotalAssist pages block automated checks and were read with a headless browser; both funds were closed that day, as were HealthWell's and Good Days' pancreatic cancer funds, which are not listed.